Cannabinoid pharmacology: implications for additional
cannabinoid receptor subtypes
Wiley JL, Martin BR.
Department of Pharmacology and Toxicology,
Medical College of Virginia,
Virginia Commonwealth University,
P.O. Box 980613, 23298-0613,
Richmond, VA, USA
Chem Phys Lipids 2002 Dec;121(1-2):57-63
ABSTRACTDelta(9)-Tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive constituent of marijuana (Cannabis sativa), is known to bind to two cannabinoid receptors: CB(1) receptors, located primarily in the brain, and CB(2) receptors, located primarily in the periphery. Recent research has suggested that other cannabinoids, including anandamide and WIN 55,212-2, may also act at novel non-CB(1), non-CB(2) cannabinoid receptor(s). Anandamide produces a number of in vivo pharmacological effects in CB(1) knockout mice that are not produced by Delta(9)-THC and cannot be explained by anandamide's rapid metabolism. In addition, in vitro anandamide and WIN 55,212-2 stimulate [35S]GTPgammaS binding in both CB(1) knockout and wildtype mice while Delta(9)-THC stimulates this binding only in wildtype mice. Although anandamide and vanilloid agonists share pharmacological effects, anandamide's actions in CB(1) knockout mice do not appear to be mediated by vanilloid VR(1) receptors. While not yet conclusive, these results suggest the possibility of additional cannabinoid receptors in the brain and periphery.Anandamide
Stoned as a newt?
The nectar of delight
Cannabis and schizophrenia
Distribution of the cannabis receptors
Cannabis receptors: invertebrate origins
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family